NeuroOne receives FDA 510(k) clearance for OneRF Trigeminal Nerve Ablation System

NEUROONE MEDICAL TECHNOLOGIES Corp

FDA 510(k) clearance granted for OneRF Trigeminal Nerve Ablation System.
System used for radiofrequency lesions to treat pain and functional neurosurgery.
Clearance announced on August 18, 2025.

item 8.01

Source: SEC EDGAR

accession 0001213900-25-077726

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.